课题基金 / 基金详情

ORAL CP 99,219 IN CHRONIC HEPATIC INSUFFICIENCY AND HEALTHY SUBJECTS

ORAL CP 99,219 IN CHRONIC HEPATIC INSUFFICIENCY AND HEALTHY SUBJECTS
慢性肝功能不全和健康受试者的口服 CP 99,219
批准号：
6246312
负责人：
KARL E ANDERSON
金额：
$2.71万
依托单位：
UNIVERSITY OF TEXAS MED BR GALVESTON
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-01-06 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6246312
关键词：
antibiotics antipyrine caffeine clearance rate clinical research drug screening /evaluation human subject human therapy evaluation liver cirrhosis liver disorder chemotherapy liver function oral administration pharmacokinetics

项目摘要

项目成果

KARL E ANDERSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
CP-99,219 a new antibiotic related to fluoroquinolones such as ciprofloxacin, norfloxacin and oflozacin is eliminated primarily by the liver. Preclinical data suggest CP-99,219 may be useful in treating bacterial peritonitis, a common complication of liver disease. It is of interest to compare the safety, toleration & pharmacokinetics of the drug in patients with liver disease & healthy subjects. In this study, single & multiple dose pharmacokinetics & plasma protein binding will be compared in cirrhotics & age, sex & weight-matched healthy subjects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CHARACTERIZATION OF ENZYME DEFECTS IN PORPHYRIAS
STUDIES IN PORPHYRIA III, HEME, AND TIN MESOPORPHYRIN IN ACUTE PORPHYRIAS
HEME ARGINATE IN ACUTE PORPHYRIA
STUDIES IN PORPHYRIA CUTANEA TARDA
海外基金